NEVRO CORP's ticker is NVRO and the CUSIP is 64157F103. A total of 184 filers reported holding NEVRO CORP in Q3 2017. The put-call ratio across all filers is 0.65 and the average weighting 0.2%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q2 2018 | $18,334,000 | -14.9% | 229,608 | -7.7% | 1.04% | -13.1% |
Q1 2018 | $21,552,000 | +1.1% | 248,673 | -19.5% | 1.20% | +17.6% |
Q4 2017 | $21,321,000 | -38.8% | 308,819 | -19.4% | 1.02% | -28.1% |
Q3 2017 | $34,829,000 | -14.8% | 383,247 | -30.2% | 1.42% | +8.6% |
Q2 2017 | $40,857,000 | -18.2% | 548,935 | +3.0% | 1.30% | -22.3% |
Q1 2017 | $49,940,000 | +55.9% | 532,983 | +20.9% | 1.68% | +61.6% |
Q4 2016 | $32,030,000 | -35.1% | 440,818 | -6.8% | 1.04% | -19.0% |
Q3 2016 | $49,371,000 | +25.5% | 472,940 | -11.3% | 1.28% | +26.7% |
Q2 2016 | $39,341,000 | -35.8% | 533,364 | -51.0% | 1.01% | +28.5% |
Q1 2016 | $61,278,000 | +130.0% | 1,089,180 | +176.0% | 0.79% | +23.4% |
Q4 2015 | $26,641,000 | +45.5% | 394,636 | +0.0% | 0.64% | +46.3% |
Q3 2015 | $18,307,000 | -13.8% | 394,635 | -0.2% | 0.44% | -3.3% |
Q2 2015 | $21,248,000 | +249.0% | 395,311 | +211.2% | 0.45% | +229.2% |
Q1 2015 | $6,089,000 | – | 127,038 | – | 0.14% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Broadfin Capital, LLC | 622,615 | $38,920,000 | 8.04% |
Tamarack Advisers, LP | 160,000 | $10,002,000 | 3.97% |
Birch Run Capital Advisors, LP | 187,425 | $11,716,000 | 3.72% |
Prosight Management, LP | 128,765 | $8,049,000 | 3.52% |
Ratan Capital Management LP | 38,653 | $2,416,000 | 3.44% |
DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 579,463 | $36,222,000 | 1.39% |
Spark Investment Management LLC | 403,400 | $25,216,000 | 1.17% |
Sivik Global Healthcare LLC | 50,000 | $3,126,000 | 1.15% |
ArrowMark Colorado Holdings LLC | 1,882,009 | $117,644,000 | 1.11% |
PFM Health Sciences, LP | 721,229 | $45,084,000 | 1.00% |